Rhinomed (ASX:RNO) Total Stockholders Equity : A$-6.41 Mil (As of Jun. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Rhinomed Total Stockholders Equity?

Rhinomed's Total Stockholders Equity for the quarter that ended in Jun. 2023 was A$-6.41 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Rhinomed's Book Value per Share for the quarter that ended in Jun. 2023 was A$-0.02. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Rhinomed's Debt-to-Equity for the quarter that ended in Jun. 2023 was -0.93.

Rhinomed Total Stockholders Equity Historical Data

The historical data trend for Rhinomed's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rhinomed Total Stockholders Equity Chart

Rhinomed Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Total Stockholders Equity

Get a 7-Day Free Trial

4.62

10.86

4.76

5.04

-6.41

Rhinomed Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Total Stockholders Equity	Get a 7-Day Free Trial															4.76	3.24	5.04	0.21	-6.41

Rhinomed (ASX:RNO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Rhinomed's Book Value per Share for the quarter that ended in Jun. 2023 is

Book Value per Share	=	(Total Stockholders Equity	-	Preferred Stock)	/	Shares Outstanding (EOP)
	=	(-6.406	-	0)	/	285.72
	=	-0.02

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Rhinomed's Debt-to-Equity for the quarter that ended in Jun. 2023 is

Debt-to-Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.961	+	0.015)	/	-6.406
	=	-0.93

Rhinomed Total Stockholders Equity Related Terms

Thank you for viewing the detailed overview of Rhinomed's Total Stockholders Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Rhinomed (ASX:RNO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rhinomed Ltd (ASX:RNO) » Definitions » Total Stockholders Equity

Comparable Companies

Traded in Other Exchanges

RHNMF:USA

Address

132 Gwynne Street, Level 1, Cremorne, VIC, AUS, 3121

Website

https://www.rhinomed.global

Rhinomed Ltd is a medical technology company, with a patented nasal technology platform. It is engaged in the research, development and commercialization of consumer and medical devices including nasal, respiratory and nasal drug delivery technologies. It operates in one segment which is the identification, acquisition, and commercialization of late-stage consumer therapeutic and medical delivery technologies. The products of the company involve Rhinoswab, Mute, Turbine and Rhinoswab Junior. It operates geographically within North, Central, and South America, Asia-Pacific, Europe, Middle East, and Africa. The company earns majority of its revenue from Asia-Pacific.

Rhinomed (ASX:RNO) Headlines

No Headlines